Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
NeoImmuneTech
Hoffmann-La Roche
Eastern Cooperative Oncology Group
Emory University
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
AstraZeneca
University of California, San Diego
Emory University
Pfizer
Akamis Bio
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Seattle Children's Hospital
Providence Health & Services
Regeneron Pharmaceuticals
Intensity Therapeutics, Inc.
Vaccinex Inc.
National Cancer Institute (NCI)
Providence Health & Services
Simcha IL-18, Inc.
Atara Biotherapeutics
UNICANCER
Hoosier Cancer Research Network
R-Pharm
Evopoint Biosciences Inc.
Icahn School of Medicine at Mount Sinai
Kineta Inc.
H. Lee Moffitt Cancer Center and Research Institute
Genocea Biosciences, Inc.
Assistance Publique - Hôpitaux de Paris
MultiVir, Inc.
Merck Sharp & Dohme LLC